Signal from the log
Claris Biotherapeutics
118 M$ · Series B · United States · Biotech
Claris Biotherapeutics développe un collyre biologique contre la sécheresse oculaire neurotrophique, une maladie de la surface de l'œil sans traitement satisfaisant. Série B de 118 M$ menée par Samsara BioCapital et Catalio Capital Management.
Article
Announced on , logged by the watch of 8 August 2026.
- Operation
- Funding round
- Announced amount
- 118 M$
- Stage
- Series B
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by Samsara Biocapital , Catalio Capital Management , with Adage Capital Management , Sofinnova Investments , Aisling Capital , ADAR1 Capital Management
Provenance
Source journal-veille.md
Logged on 8 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.